FBXO44 and neoplasm: Targeting FBXO44 by genetic knockdown or pharmacologic inhibition of SUV39H1 restrained the proliferation of breast, lung, colon, and glioblastoma cancer cells in vitro and tumor growth in immunodeficient mice.